Now showing items 2741-2760 of 2900

    • Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal. 

      Turajlic, S; Xu, H; Litchfield, K; Rowan, A; Chambers, T; Lopez, JI; Nicol, D; O'Brien, T; Larkin, J; Horswell, S; Stares, M; Au, L; Jamal-Hanjani, M; Challacombe, B; Chandra, A; Hazell, S; Eichler-Jonsson, C; Soultati, A; Chowdhury, S; Rudman, S; Lynch, J; Fernando, A; Stamp, G; Nye, E; Jabbar, F; Spain, L; Lall, S; Guarch, R; Falzon, M; Proctor, I; Pickering, L; Gore, M; Watkins, TBK; Ward, S; Stewart, A; DiNatale, R; Becerra, MF; Reznik, E; Hsieh, JJ; Richmond, TA; Mayhew, GF; Hill, SM; McNally, CD; Jones, C; Rosenbaum, H; Stanislaw, S; Burgess, DL; Alexander, NR; Swanton, C; PEACE; TRACERx Renal Consortium (2018-04-19)
      Clear-cell renal cell carcinoma (ccRCC) exhibits a broad range of metastatic phenotypes that have not been systematically studied to date. Here, we analyzed 575 primary and 335 metastatic biopsies across 100 patients with ...
    • Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer. 

      Fribbens, C; Garcia Murillas, I; Beaney, M; Hrebien, S; O'Leary, B; Kilburn, L; Howarth, K; Epstein, M; Green, E; Rosenfeld, N; Ring, A; Johnston, S; Turner, N (2018-01-01)
      Background: Selection of resistance mutations may play a major role in the development of endocrine resistance. ESR1 mutations are rare in primary breast cancer but have high prevalence in patients treated with aromatase ...
    • Tracking the Evolution of Non-Small-Cell Lung Cancer. 

      Jamal-Hanjani, M; Wilson, GA; McGranahan, N; Birkbak, NJ; Watkins, TBK; Veeriah, S; Shafi, S; Johnson, DH; Mitter, R; Rosenthal, R; Salm, M; Horswell, S; Escudero, M; Matthews, N; Rowan, A; Chambers, T; Moore, DA; Turajlic, S; Xu, H; Lee, S-M; Forster, MD; Ahmad, T; Hiley, CT; Abbosh, C; Falzon, M; Borg, E; Marafioti, T; Lawrence, D; Hayward, M; Kolvekar, S; Panagiotopoulos, N; Janes, SM; Thakrar, R; Ahmed, A; Blackhall, F; Summers, Y; Shah, R; Joseph, L; Quinn, AM; Crosbie, PA; Naidu, B; Middleton, G; Langman, G; Trotter, S; Nicolson, M; Remmen, H; Kerr, K; Chetty, M; Gomersall, L; Fennell, DA; Nakas, A; Rathinam, S; Anand, G; Khan, S; Russell, P; Ezhil, V; Ismail, B; Irvin-Sellers, M; Prakash, V; Lester, JF; Kornaszewska, M; Attanoos, R; Adams, H; Davies, H; Dentro, S; Taniere, P; O'Sullivan, B; Lowe, HL; Hartley, JA; Iles, N; Bell, H; Ngai, Y; Shaw, JA; Herrero, J; Szallasi, Z; Schwarz, RF; Stewart, A; Quezada, SA; Le Quesne, J; Van Loo, P; Dive, C; Hackshaw, A; Swanton, C; TRACERx Consortium (2017-06-01)
      BACKGROUND: Among patients with non-small-cell lung cancer (NSCLC), data on intratumor heterogeneity and cancer genome evolution have been limited to small retrospective cohorts. We wanted to prospectively investigate ...
    • Transanal Total Mesorectal Excision 

      Penna, M; Hompes, R; Arnold, S; Wynn, G; Austin, R; Warusavitarne, J; Moran, B; Hanna, GB; Mortensen, NJ; Tekkis, PP (Ovid Technologies (Wolters Kluwer Health), 2017-07)
    • Transcription factor-mediated lineage switching reveals plasticity in primary committed progenitor cells 

      Heyworth, C; Pearson, S; May, G; Enver, T (2002-07-15)
      The developmental plasticity of transplanted adult stem cells challenges the notion that tissue-restricted stem cells have stringently limited lineage potential and prompts a re-evaluation of the stability of lineage ...
    • Transcription factors link mouse WAP-T mammary tumors with human breast cancer 

      Gevensleben, Heidrun (2013-03)
      Mouse models are important tools to decipher the molecular mechanisms of mammary carcinogenesis and to mimic the respective human disease. Despite sharing common phenotypic and genetic features, the proper translation of ...
    • Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies 

      Syed, N; Smith, P; Sullivan, A; Spender, LC; Dyer, M; Karran, L; O Nions, J; Allday, M; Hoffmann, I; Crawford, D; Griffin, B; Farrell, PJ; Crook, T (AMER SOC HEMATOLOGY, 2006-01-01)
      The Polo-like kinases (Plks) are a highly conserved family of protein kinases that function in regulation of cell cycle and DNA damage-induced checkpoints. Evidence of a tumor suppressor function for the Plks in human ...
    • Transcriptional targeting of acute hypoxia in the tumour stroma is a novel and viable strategy for cancer gene therapy 

      Ingram, N; Porter, CD (2005-07)
      Deregulated tumour growth and neovascularization result in an inadequate tumour blood supply, leading to areas of chronic hypoxia and necrosis. Irregular vascular structure and abnormal tumour physiology also cause erratic ...
    • A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. 

      Wu, L; Shi, W; Long, J; Guo, X; Michailidou, K; Beesley, J; Bolla, MK; Shu, X-O; Lu, Y; Cai, Q; Al-Ejeh, F; Rozali, E; Wang, Q; Dennis, J; Li, B; Zeng, C; Feng, H; Gusev, A; Barfield, RT; Andrulis, IL; Anton-Culver, H; Arndt, V; Aronson, KJ; Auer, PL; Barrdahl, M; Baynes, C; Beckmann, MW; Benitez, J; Bermisheva, M; Blomqvist, C; Bogdanova, NV; Bojesen, SE; Brauch, H; Brenner, H; Brinton, L; Broberg, P; Brucker, SY; Burwinkel, B; Caldés, T; Canzian, F; Carter, BD; Castelao, JE; Chang-Claude, J; Chen, X; Cheng, T-YD; Christiansen, H; Clarke, CL; NBCS Collaborators; Collée, M; Cornelissen, S; Couch, FJ; Cox, D; Cox, A; Cross, SS; Cunningham, JM; Czene, K; Daly, MB; Devilee, P; Doheny, KF; Dörk, T; Dos-Santos-Silva, I; Dumont, M; Dwek, M; Eccles, DM; Eilber, U; Eliassen, AH; Engel, C; Eriksson, M; Fachal, L; Fasching, PA; Figueroa, J; Flesch-Janys, D; Fletcher, O; Flyger, H; Fritschi, L; Gabrielson, M; Gago-Dominguez, M; Gapstur, SM; García-Closas, M; Gaudet, MM; Ghoussaini, M; Giles, GG; Goldberg, MS; Goldgar, DE; González-Neira, A; Guénel, P; Hahnen, E; Haiman, CA; Håkansson, N; Hall, P; Hallberg, E; Hamann, U; Harrington, P; Hein, A; Hicks, B; Hillemanns, P; Hollestelle, A; Hoover, RN; Hopper, JL; Huang, G; Humphreys, K; Hunter, DJ; Jakubowska, A; Janni, W; John, EM; Johnson, N; Jones, K; Jones, ME; Jung, A; Kaaks, R; Kerin, MJ; Khusnutdinova, E; Kosma, V-M; Kristensen, VN; Lambrechts, D; Le Marchand, L; Li, J; Lindström, S; Lissowska, J; Lo, W-Y; Loibl, S; Lubinski, J; Luccarini, C; Lux, MP; MacInnis, RJ; Maishman, T; Kostovska, IM; Mannermaa, A; Manson, JE; Margolin, S; Mavroudis, D; Meijers-Heijboer, H; Meindl, A; Menon, U; Meyer, J; Mulligan, AM; Neuhausen, SL; Nevanlinna, H; Neven, P; Nielsen, SF; Nordestgaard, BG; Olopade, OI; Olson, JE; Olsson, H; Peterlongo, P; Peto, J; Plaseska-Karanfilska, D; Prentice, R; Presneau, N; Pylkäs, K; Rack, B; Radice, P; Rahman, N; Rennert, G; Rennert, HS; Rhenius, V; Romero, A; Romm, J; Rudolph, A; Saloustros, E; Sandler, DP; Sawyer, EJ; Schmidt, MK; Schmutzler, RK; Schneeweiss, A; Scott, RJ; Scott, CG; Seal, S; Shah, M; Shrubsole, MJ; Smeets, A; Southey, MC; Spinelli, JJ; Stone, J; Surowy, H; Swerdlow, AJ; Tamimi, RM; Tapper, W; Taylor, JA; Terry, MB; Tessier, DC; Thomas, A; Thöne, K; Tollenaar, RAEM; Torres, D; Truong, T; Untch, M; Vachon, C; Van Den Berg, D; Vincent, D; Waisfisz, Q; Weinberg, CR; Wendt, C; Whittemore, AS; Wildiers, H; Willett, WC; Winqvist, R; Wolk, A; Xia, L; Yang, XR; Ziogas, A; Ziv, E; kConFab/AOCS Investigators; Dunning, AM; Pharoah, PDP; Simard, J; Milne, RL; Edwards, SL; Kraft, P; Easton, DF; Chenevix-Trench, G; Zheng, W (2018-07)
      The breast cancer risk variants identified in genome-wide association studies explain only a small fraction of the familial relative risk, and the genes responsible for these associations remain largely unknown. To identify ...
    • Transcriptomic analysis of tubular carcinomas of the breast reveals similarities and differences with molecular subtype-matched ductal and lobular carcinomas. 

      Lopez-Garcia, MA; Geyer, FC; Natrajan, R; Kreike, B; Mackay, A; Grigoriadis, A; Reis-Filho, JS; Weigelt, B (2010-09)
      Tubular carcinoma (TC) is an uncommon special type of breast cancer characterized by an indolent clinical course. Although described as part of a spectrum of related lesions named 'low-grade breast neoplasia family' due ...
    • Transferring patients home to die: what is the potential population in UK critical care units? 

      Coombs, MA; Darlington, A-SE; Long-Sutehall, T; Pattison, N; Richardson, A (BMJ, 2017-03)
    • Transformation of T-cell large granular lymphocyte leukaemia into a high-grade large T-cell lymphoma 

      Matutes, E; Wotherspoon, AC; Parker, NE; Osuji, N; Isaacson, PG; Catovsky, D (WILEY-BLACKWELL, 2001-12)
      We describe a case of T-cell large granular lymphocyte (LGL) leukaemia that transformed into a large-cell T-cell lymphoma 11 years from diagnosis. A 29-year-old asymptomatic female presented in 1989 with lymphocytosis, ...
    • TransHERA: The cell cycle regulator p27 predicts benefit from trastuzumab treatment in HER2-positive early breast cancer patients treated within the HERA trial 

      Filipits, M; Gnant, M; Dafni, U; Polydoropoulou, V; Hills, MJ; Leyland-Jones, B; Piccart-Gebhart, M; Dowsett, M (2015-05-01)
    • Translational research and the changing face of breast cancer. 

      Dowsett, M (2004-01)
      Advances in our understanding of the molecular mechanisms underlying breast cancer have identified a considerable number of new molecular targets that may have significant roles in tumor behavior. The rapid and effective ...
    • Translocation between chromosome 5q35 and chromosome 11q13 - an unusual cytogenetic finding in a primary refractory acute myeloid leukemia 

      Wang, TF; Horsley, SW; Lee, KF; Chu, SC; Li, CC; Kao, RH (2006-06)
      Cytogenetic abnormalities are observed in approximately two-thirds of patients with acute myeloid leukemia (AML). Chromosome rearrangements are associated with specific subtypes of AML and associated prognosis. We report ...
    • Translocation t(2;7)(p12;q21-22) with dysregulation of the CDK6 gene mapping to 7q21-22 in a non-Hodgkin’s lymphoma with leukemia 

      Brito-Babapulle, V; Gruszka-Westwood, AM; Platt, G; Andersen, CL; Elnenaei, MO; Matutes, E; Wotherspoon, AC; Weston-Smith, SG; Catovsky, D (2002-04)
      Background and Objectives. A female patient presented with splenomegaly and lymphocytosis with atypical lymphoid cell morphology, We identified t(2;7)(p12;q21) prompting studies of the translocation breakpoint and its ...
    • TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer. 

      James, N; Pirrie, S; Pope, A; Barton, D; Andronis, L; Goranitis, I; Collins, S; McLaren, D; O'Sullivan, J; Parker, C; Porfiri, E; Staffurth, J; Stanley, A; Wylie, J; Beesley, S; Birtle, A; Brown, J; Chakraborti, P; Russell, M; Billingham, L (2016-07)
      Bony metastatic castration-refractory prostate cancer is associated with a poor prognosis and high morbidity. TRAPEZE was a two-by-two factorial randomised controlled trial of zoledronic acid (ZA) and strontium-89 (Sr-89), ...
    • Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+metastatic breast cancer 

      Niculescu-Duvaz, I (2010)
      Roche Holding AG, and its subsidiaries Genentech Inc and Chugai Pharmaceutical Co Ltd, are developing trastuzumab emtansine (trastuzumab-DM1) for the treatment of HER2+ metastatic breast cancer. Trastuzumab emtansine is a ...